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Summary Although small cell lung cancer (SCLC) is very chemosensitive, cerebral metastases are treated
with radiotherapy in the belief that they are protected from chemotherapy by the blood-brain barrier (BBB).
The validity of this assumption has not been tested in clinical practice. In a randomised trial of treatment in
610 patients with SCLC, 19 patients who had symptomatic cerebral metastases at presentation were treated
initially with chemotherapy, and cranial irradiation withheld. Chemotherapy was cyclophosphamide I g m 2
i.v. day 1, vincristine 2mg i.v. day I and etoposide 100mg tds p.o. days 1-3, repeated every 21 days, with
response assessed objectively by computerised tomography (CT) or radionuclide brain scan, and by clinical
examination. A post-chemotherapy scan was obtained in 14 patients, eight of whom achieved a partial
remission and one a complete remission of the cerebral metastases. The radiologically proven responses were
sustained and accompanied by rapid neurological improvement. Of the remaining five patients who were
assessed by clinical examination alone, one had improved neurological function after chemotherapy. The
response rate for SCLC cerebral metastases treated with chemotherapy was therefore 10/19 (53%).
Chemotherapy has the advantage over cranial irradiation of simultaneously treating both cerebral metastases
and extracranial disease. The place of chemotherapy in the management of cerebral metastases in this and
other chemosensitive tumours should be reconsidered since these findings indicate that the BBB does not
prevent response to chemotherapy.
Between 4 and 19% of patients with small cell lung cancer
(SCLC) have cerebral metastases at presentation, and up to
30% develop clinically apparent brain metastases during the
course of their illness (Nugent et al., 1979; Hirsch et al.,
1983). This relatively high incidence of cerebral metastases as
a site of relapse has led to the brain being considered a
(sanctuary site' for SCLC, protected from systemic
chemotherapy by the blood-brain barrier (BBB). In normal
brain the BBB is maintained by tight connections between
endothelial cells, but cerebral metastases derive their blood
supply from new capillaries growing into the tumour (Folk-
man, 1976) which have endothelial fenestrations and gaps
(Long et al., 1979). Indeed the increased permeability of
tumour vessels to radiolabelled colloids and CT contrast
media is fundamental to the radiological diagnosis of cereb-
ral metastases. Despite this, when treating cerebral meta-
stases it is often assumed that, because most cytotoxic drugs
do not cross the intact BBB, chemotherapy will be ineffective.
Even in SCLC, which is a highly chemosensitive tumour,
chemotherapy has been largely ignored in the management of
cerebral metastases, these patients being treated with steriods
and cranial irradiation (Cox et al., 1980). There are reports
of radiologically proven responses of cerebral metastases to
systemic chemotherapy in SCLC (Kantarjian et al., 1984;
Postmus et al., 1987; Kristiansen & Hansen, 1988) but the
response rate to a single regimen is not known. However, the
only systematic study of conventional chemotherapy for
cerebral metastases (Rosner et al., 1986) showed that cerebral
metastases from breast cancer have the same frequency of
response as secondary deposits at other sites.
Our aim was to assess in a prospective study the objective
response rate of cerebral metastases in previously untreated
SCLC patients who received uniform chemotherapy, rather
than radiotherapy, as initial treatment.
Methods
Between February 1982 and September 1985, 610 patients
with histologically or cytologically confirmed SCLC entered a
multicentre randomised chemotherapy trial (Spiro et al.,
1989). They had no past history of malignancy and had not
received previous radiotherapy or chemotherapy. Brain scans
were not performed routinely, and only patients with symp-
toms or signs of cerebral metastases at presentation had a
CT or radionuclide brain scan before starting treatment.
Cerebral metastases were diagnosed by the presence of
enhanced lesions on CT or areas of increased uptake on
isotope brain scan, compatible with the clinical findings. In
these patients, cranial irradiation was withheld and initial
treatment was with chemotherapy. Patients with a severe
neurological deficit received oral dexamethasone, but if
possible the dose was reduced during the course of
chemotherapy. Steroids were not used as anti-emetics. The
chemotherapy was cyclophosphamide I g m-2 i.v. day 1, vin-
cristine 2 mg i.v. day I and etoposide 100 mg tds p.o. days
1-3. If possible the CT scan was repeated before the second
cycle of chemotherapy, and it was planned that all patients
be evaluated with a further scan after four cycles of
chemotherapy.
The study was designed to assess the response of cerebral
metastases to chemotherapy. Once response had been
assessed, patients could then receive conventional treatment
with cranial radiotherapy either whilst in remission, or on
progression. Patients who achieved an overall complete (CR)
or partial response (PR) including a cranial response when
assessed after the fourth cycle of chemotherapy, were eligible
for cranial irradiation while in remission (20 Gy in five frac-
tions). Clinical progression of cerebral metastases was
confirmed if possible on CT scan and patients were treated
with steroids and cranial irradiation (20 Gy in five fractions)
where appropriate. Post-mortem examinations were not per-
formed routinely.
The response of cerebral metastases to chemotherapy was
assessed by changes in the size and number of enhanced
lesions on CT scan or 'hot spots' on radionuclide scan. In
each patient the same scanning modality was used for
baseline and follow-up examinations: (1) Complete remission
(CR) - no evidence of cerebral metastases on enhanced CT
or isotope brain scan. (2) Partial remission (PR) - more than
50% reduction in the sum of the maximum two-dimensional
measurements of all cerebral metastases, and no new lesions
seen. (3) Stable disease (SD) - no change in the number or
size of cerebral metastases. (4) Progressive disease (PD) - an
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increase in the size of cerebral metastases, or the appearance a
of new lesions.
Neurological signs and symptoms were recorded on pres-
entation, at each cycle ofchemotherapy, and 3-weekly during
follow-up. A clinical response was defined as a definite imp-
rovement in neurological function maintained for at least 1
month, either without steroids or on a reducing dose of
steroids. The toxicity of chemotherapy treatment was
evaluated by WHO criteria (1979).
Results
Twenty-five patients (4.1%) had symptomatic cerebal meta-
stases at presentation. Six patients were excluded from the
analysis of response to chemotherapy, four who were initially
treated with cranial irradiation before being referred to the
study centre, and two who underwent craniotomy before
chemotherapy. The effect of chemotherapy on cerebral
metastases could be assessed in the remaining 19 evaluable
patients whose characteristics on entry to the study are b
shown in Table I.
Response to chemotherapy
All 19 evaluable patients had a CT or isotope scan before
chemotherapy. In 14/19 patients a second brain scan was
obtained after chemotherapy. In these 14 radiologically
assessable patients, nine had responded after four cycles of
chemotherapy. Of these, eight had a partial response assessed
by CT scanning and one a complete response on repeat
isotope brain scan. The remaining five radiologically assess-
able patients were non-responders. An additional CT scan
was obtained after a single cycle of treatment in nine of the
14 radiologically assessable patients. Of these, five showed a
response at this early stage. All nine patients with radio-
logically proven response also had improvement of their
neurological function.
Five of 19 patients did not have a second scan. Four of
these had rapid deterioration in neurological state, and pro-
gression of disease at other sites. The remaining patient had a
clear improvement in neurological state with complete resolu-
tion of ataxia and headaches. This patient is considered as a
clinical responder.
The overall response was therefore 10/19 (53%). Only
three of the 10 responders (nine radiological, one clinical)
were given steroids and these were discontinued before res-
ponse was assessed. The response of the intrathoracic tumour
was 15/19 (79%). The five patients who responded in the
chest but not in the brain were not clinically distinguishable
from the patients who responded at both sites.
Figure 1 shows a series ofenhanced CT brain scans from a
man with SCLC who presented with headache and left-sided
weakness. A large right frontal metastasis, and a smaller left
parietal lesion were present before chemotherapy. Both were
markedly smaller following the first cycle of chemotherapy
and after four cycles of chemotherapy only a frontal low
density area, with no enhancement, remained. His
Table I Patient characteristics on entry to the study
Number 19
Median age (years) 60 (41 -71)
Male/female 13/6
Performance status (ECOG)
0 3
1 7
2 4
3 4
4 1
Brain scan at diagnosis
CT 16
Radionuclide 3
Disease sites at diagnosis
Brain and chest only 8
More widespread 11
._S_
Figure 1 Enhanced CT brain scan (a) before chemotherapy, (b)
after one cycle and (c) after four cycles of chemotherapy.
neurological symptoms resolved after the first cycle of
chemotherapy.
Duration ofresponse and survival
For the 10 patients who responded to chemotherapy, the
duration of response for cerebral metastases is shown in
Table II. In the five patients who received cranial irradiation
while in remission, the duration of response of cerebral
metastases to chemotherapy can only be measured to the
time of radiotherapy. For the remaining five patients, dura-
tion of response was measured until the time of cerebralCEREBRAL METASTASES OF SCLC 149
Table II Response duration, timing of cranial irradiation and
survival
Duration ofresponse Cranial irradiation
Patient to chemotherapy Survival
no. (weeks) In remission At relapse (weeks)
1 37 - + 51
2 16 - - 19
3 19 + - 60
4 28 + - 32
5 19 + - 22
6 16 + - 27
7 25 - - 28
8 10 - - 14
9 38 - + 62
15 12 + - 49
progression or death. The median survival for all 19 patients
presenting with cerebral metastases and treated first with
chemotherapy was 28 weeks (range 1-68 weeks). Median
survival for all patients with extensive disease in the trial was
32 weeks (Spiro et al., 1989).
Toxicity ofchemotherapy
Treatment toxicity was similar to that experienced by other
patients receiving the same chemotherapy regimen (Spiro et
al., 1989). All patients experienced mild to moderate nausea
and vomiting (WHO grade I-IIl) on day 1 of each
chemotherapy cycle, but none had prolonged or intractable
vomiting (grade IV). Hair loss after chemotherapy was
marked (grade 111), but reversible in all patients. One patient
died suddenly at home on day 9 of the first treatment cycle.
Post-mortem examination was not carried out, but the likely
cause of death was overwhelming infection due to myelo-
suppression following chemotherapy. There were no other
episodes of severe (grade IV) myelosuppression or life-
threatening infection (grade IV).
Discussion
SCLC is a highly chemoresponsive disease which is usually
disseminated at diagnosis, and chemotherapy is now estab-
lished as the main method of treatment (Spiro, 1985). Cereb-
ral metastases are regarded as an exception to this rule,
conventional treatment being with radiotherapy in the belief
that such metastases are protected from systemic
chemotherapy by the BBB. Undoubtedly tight capillary
endothelial junctions do maintain the BBB in normal brain
(Brightman & Reese, 1969), but increased tumour vessel
permeability is the basis for diagnosing cerebral metastases
by radionucleide brain scan or enhanced CT scan. Tumours
produce angiogenic factors (Folkman, 1976) and derive their
blood supply from new vessels growing into the tumour.
Endothelial gaps are present in the tumour vessels (Long,
1979), implying that cerebral metastases do not lie beyond
the BBB.
The prognosis for SCLC patients with cerebral metastases
who are treated by cranial irradiation is poor, and many
have a dismal quality of life (Felletti et al., 1985; Lucas et al.,
1986). The brain is rarely the sole site of metastasis in SCLC
(Nugent et al., 1979), and patients receiving cranial irradia-
tion alone often die of extra-cranial tumour rather than
cerebral metastases (Cairncross et al., 1980). Nevertheless,
there are only a few reports of SCLC cerebral metastases
responding to conventional chemotherapy (Kantarjian et al.,
1984; Kristjansen & Hansen, 1988), and a single study of
treatment with high-dose chemotherapy (Postmus et al.,
1987). The question we have asked is how often do SCLC
cerebral metastases respond to a single conventional
chemotherapy regimen, used in place of radiotherapy as
initial treatment. We have studied untreated patients with
SCLC and symptomatic cerebral metastases at presentation
who received uniform chemotherapy with response assessed
objectively by serial CT or radionucleide brain scans.
The response rate for cerebral metastases in these patients
treated with conventional combination chemotherapy alone
was 53%. In a recent study of SCLC patients with brain
metastases, Kristjansen & Hansen (1988) reported responses
to chemotherapy in all seven evaluable patients. However, a
variety of chemotherapy regimens were used, and all patients
initially received high dose steriods. Postmus et al. (1987)
demonstrated responses in four of nine evaluable SCLC
patients with cerebral metastases given high dose etoposide
to overcome the BBB which is normally impermeable to
etoposide (Creave, 1982). In contrast to the present study,
many of their patients had relapsed after cranial irradiation
or received previous chemotherapy, and the toxicity of high-
dose etoposide was considerable. Our results in a larger,
well-defined, group receiving uniform, conventional
chemotherapy provide a clear indication of the respons-
iveness of SCLC cerebral metastases.
It is possible that the response rate for cerebral metastases
is lower than for the primary tumour. However, the numbers
of patients studied are small and there are technical
difficulties in assessing the response of intracranial tumours
to treatment. By combining the results of CT and radionu-
clide brain scans with neurological examination a relatively
accurate assessment of response can be achieved (Levin et al.,
1977). The distinction between CR and PR remains difficult
because damage to neurological tissues may persist despite
successful treatment. The difference in response rate between
the brain and primary tumour may, however, be genuine.
Studies of experimental brain tumours in animals have
shown that the BBB may be preserved in very small metas-
tases and also at the margins of larger deposits (Hasegawa et
al., 1983). The relationship between cerebral metastases, the
vascular endothelium and drug delivery is therefore complex
(Greig, 1987).
None of the drugs used in this study crosses the BBB easily
in normal brain (Workman, 1986). The present study, and
that of Rosner et al. (1986) in breast cancer, which show
response rates in the brain similar to those at other sites of
metastatic disease, suggest the hypothesis that the BBB is not
the most important consideration in treating cerebral meta-
stases. Indeed, the term BBB is a misnomer in cerebral
metastases: blood-tumour barrier is a more appropriate de-
scription.
To be useful in clinical practice, responses to
chemotherapy must be rapid, accompanied by clinical imp-
rovement, and sustained. In our study, CT scans repeated
after just one cycle of chemotherapy showed a definite res-
ponse, which was accompanied by improvement of
neurological signs. We cannot comment directly on response
duration because the study design included the option of
cranial irradiation for patients who had responded to
chemotherapy. The policy of chemotherapy as initial treat-
ment for brain metastases has not been compared with initial
radiotherapy in a randomised trial, but we have not found
evidence of a detriment in survival (Cox et al., 1980; Gian-
none et al., 1987).
The place of chemotherapy in treating patients with cereb-
ral metastases in this and other cancers will be determined by
the chemosensitivity of the primary tumour, the presence of
extracranial disease and the effectiveness of conventional
treatment with cranial irradiation. In chemosensitive tumours
such as SCLC, where the treatment is palliative and extra-
cranial disease almost invariably present, initial treatment
with chemotherapy may have several advantages over cranial
irradiation. Chemotherapy may start immediately and simul-
taneously treats both cerebral metastases and other sites of
disease. This is important because many patients treated by
cranial radiotherapy alone die of extracranial tumour. These
patients may be spared the need for additional treatment
with cranial irradiation requiring daily travel or admission to
hospital. Finally, we have shown that after the first cycle of150 C.J. TWELVES et al.
chemotherapy, response can be assessed by CT scan and
clinical examination. If there has been no response, the
chemotherapy can be discontinued and the patient may then
be treated with cranial irradiation. Such a policy carries the
advantages of initial treatment to all sites of disease, both
primary and metastatic, with early addition of cranial
irradiation for patients in whom this is clearly necessary.
This work was supported by a grant from the Cancer Research
Campaign.
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